Posted by Michael Wonder on 26 Feb 2026
Olezarsen sNDA accepted by the FDA for priority review for the treatment of severe hypertriglyceridaemia
26 February 2026 - Ionis Pharmaceuticals today announced that the US FDA has accepted for priority review the supplemental new drug application for olezarsen for severe hypertriglyceridaemia.
The FDA has set a PDUFA target action date of 30 June 2026.
